All posts by imreal

Legal / Law: Criminal Law

Alliance of Channel Women Names Big Impact Winner for Q3 2023

Leave a comment


ACW encourages women to go on record supporting the ACW Advocacy Pledge by signing its pledge page. In addition, the association encourages visitors to nominate women who are “living the pledge.”

Corbett, the Big Impact Winner for Q3 2023, was nominated by Jennifer Redmond, Director of Sales Operations at Fusion Connect.

“Staci Corbett embodies the essence of Living the ACW Advocacy Pledge through her unwavering commitment to uplifting women in the industry. Her actions serve as a beacon of inspiration for us all,” said Redmond.

“Staci’s willingness to lend a helping hand knows no bounds. She goes above and beyond to extend her knowledge, experience and resources to her female peers, ensuring they have the tools they need to succeed. Whether it’s providing mentorship, sharing invaluable insights or simply offering a word of encouragement, Staci is a steadfast advocate for the advancement of women in the industry.”

Read the full nomination here.

Congratulations to ACW’s other Living the Pledge Q3 nominees, including:

  •     Stacey Cole, Senior Director of Global Partner Marketing at Five9
  •     Autum Grimm, Chief Revenue Officer at PartnerTap

For information about the ACW Pledge, visit: https://allianceofchannelwomen.org/engage/acw-pledge.

About the Alliance of Channel Women
Founded in 2010, the Alliance of Channel Women is a not-for-profit organization of women in the indirect sales channel of the telecom and IT industry. The Alliance of Channel Women brings us together to empower and advance women’s careers and leadership roles in the technology channel through education, community, advocacy and opportunities for personal growth. To learn more and to become a member, please visit http://www.allianceofchannelwomen.org.

Media Contact

Khali Henderson, Alliance of Channel Women, 480.848.6726, [email protected], www.allianceofchannelwomen.org

Twitter Facebook

SOURCE Alliance of Channel Women



Health

The first-of-its-kind Healthcare Spending Card¹ (offered through Lane Health) is powered by CorServ’s Payment Cards-as-a-Service API

Leave a comment


Lane Health was seeking to evolve its credit card solution with highly configurable spend controls. They wanted to add capabilities that would ensure the Card¹could be fully implemented using APIs – allowing their system to more easily communicate with the payment solution technology. The need for more powerful spend controls emphasized the necessity for an efficient and open communication path to be the most impactful solution for Lane Health customers.

Solution

Lane Health partnered with modern payment card issuing company, CorServ to launch a Visa-approved first-of-its-kind merchant-restricted health spending card. CorServ’s Payment Cards as a Service API (PCaaSA) enabled Lane Health to build the solution that was perfect for what they needed while also providing the resources and insights to navigate this typically complex process with ease. Along with the guidance, CorServ’s solution also gives Lane Health access to in-depth analytics and reporting to provide them with the insights they were looking for in order to make the Healthcare Spending Card¹ issuing program a success.

Results

The Healthcare Spending Card¹ is a highly customizable and flexible card payment solution that controls user spending based on merchant category codes. With this payment card solution, customers can use one card for their healthcare bills by simply swiping it when they have a qualified healthcare expense – medical, dental, prescriptions, or vision. If consumers link their health savings account ³ (HSA), available pre-tax funds in that account will be applied as a form of repayment. Lane Health then provides consumers with convenient repayment options over time, up to 12 months¹.

“At the core of the solution is the desire to revolutionize the way people pay for healthcare,” said Lev Peysekhman, Chief Product Officer at Lane Health. “With CorServ’s PCaaSA, we were able to create a first-of-its-kind solution and provide our customers with a convenient and impactful resource to help alleviate the stresses of healthcare expenses.”

“CorServ addressed Lane Health’s unique business need and was able to deliver and embed innovative payment card capabilities for their partners,” said Anil Goyal, CEO of CorServ. “The power of APIs enables customization to offer the best solution for your market so companies like Lane Health can innovate and succeed.”

¹ The Healthcare Spending Card and the line of credit are issued by WebBank. Card must be activated before funds can be accessed.
² Each transaction is repaid on a 12-month term (with a minimum $3 due each payment period). Transactions other than dental or hospital expenses (based on merchant category code) will be charged an origination fee of 5% and periodic finance fees. The location of the service provider is not determinative of whether a transaction is a hospital expense. Rather, transactions made within or at a hospital (including but not limited to specialists, doctors, pharmacies, etcetera, are determined to be eligible by the associated MCC and not the location of the service provider in the hospital). New Advances, if eligible, can be repaid in full or over 4 installments with no origination or periodic finance fees. Late fees apply.
³ HSAs that are linked during application must be owned and in the name of the applicant and issued by the applicant’s employer.

Media Contact

Kendall Carwile, CorServ, 6787817224, [email protected], https://www.corservsolutions.com/

SOURCE CorServ

Health

Groundbreaking Technology-Enabled Consulting Platform to Revolutionize Life Science Consulting Industry

Leave a comment


Prodigy is a result of ProPharma’s strategic investment of over $5 million in 2023 alone, reflecting the company’s dedication to innovation in the life sciences industry. This new suite of features encompasses three core capabilities:

  1. AI-Enhanced Solutions: Prodigy employs machine learning and natural language processing to enhance critical aspects of the research process. Site and patient intelligence solutions, label intelligence, health authority decision intelligence, and literature search/review have all benefited from up to 50% improvement in speed, quality, and cost. 
  2. Informatics and Advanced Analytics: Recognizing the growth in healthcare data, ProPharma has partnered with industry leaders like H1 to rapidly surface insights from massive datasets. Prodigy’s data curation engine, Prodigy LIVE, transforms raw data into standardized formats, organizing and visualizing it into automated dashboards and reports. This approach simplifies access to insights for clients and staff, shifting the focus from the collection of data towards its utility.
  3. Productivity Tools: Prodigy further delivers the automation of repetitive and mundane tasks using AI. In particular, ProPharma has integrated a large language model construct into the platform, Prodigy GPT, which enables advanced knowledge management and information processing. This reduces the time needed for data processing and increases the accuracy of results, leading to improved decision-making and enhanced productivity.

ProPharma has also published a whitepaper titled “Innovation and the Black Swan: the imperative of AI-enabled clinical research” alongside today’s announcement. The whitepaper dives into how ProPharma’s Prodigy platform addresses shortcomings of the CRO model with the new tech-enabled consulting platform. Given the explosive growth in the market, there’s a strong need for new tech advancements, like Prodigy, to provide complementary technologies to support our operational ability to flex and align our delivery model to variations across innovator size and scope.

“At ProPharma, AI-first implies democratizing access to these new resources; transforming the fabric of our business and improving the ability of our teams to drive the future of science,” says Mike Stomberg, CEO of ProPharma. “Prodigy is a testament to our commitment to navigate challenges within the life sciences industry, positioning ProPharma as a leader committed to innovation and marking a significant step forward in driving advancements in patient care through technology-enabled tools that provide sponsors a shared path to value.”

To read ProPharma’s full whitepaper, please visit https://www.propharmagroup.com/press/innovation-and-the-black-swan-prodigy-whitepaper?hs_preview=DnRydogY-151879336744 

About ProPharma
For over 20 years, ProPharma has improved the health and wellness of patients by providing advice and expertise that empowers biotech, med device, and pharmaceutical organizations of all sizes to confidently advance scientific breakthroughs and introduce new therapies. As the world’s largest RCO (Research Consulting Organization), ProPharma partners with its clients through an advise-build-operate model across the complete product lifecycle. With deep domain expertise in regulatory sciences, clinical research solutions, quality and compliance, pharmacovigilance, medical information, and R&D technology, ProPharma offers an end-to-end suite of fully customizable consulting solutions that de-risk and accelerate our partners’ most high-profile drug and device programs.

For more information about ProPharma, please visit: https://www.propharmagroup.com.

About Odyssey Investment Partners
Odyssey Investment Partners, with offices in New York and Los Angeles, is a leading private equity investment firm with more than a 25-year history of partnering with skilled managers to transform middle-market companies into more efficient and diversified businesses with strong growth profiles. Odyssey makes majority-controlled investments in industries with a long-term positive outlook and favorable secular trends.

For more information about Odyssey, please visit: https://www.odysseyinvestment.com/.

ProPharma Media Inquiries and Contacts:

Zosya Popik
Vice President, Global Marketing
ProPharma
[email protected]

Jason Wakeford
Associate Partner
Clarity for ProPharma
[email protected]

Media Contact

Jason Wakeford, Clarity for ProPharma, 424-385-4062, [email protected], https://www.propharmagroup.com/

SOURCE ProPharma

Home and Family: Marriage / Relationships

Top Boulder, CO-based corporate team joins leading distributed firm Scale LLP, following national consolidation trend

Leave a comment


Scale bolsters its Corporate & Securities practice with the addition of an experienced women-led corporate team

SAN FRANCISCO, Jan. 4, 2024 /PRNewswire-PRWeb/ — Scale LLP, the full-service, national law firm built by former Silicon-Valley tech GCs to serve high-growth companies, announced today that Katy Reamon, Channah Rose, Jenna Geuke, and Tyler Hayden, formerly of Sage Law Group, are joining the firm’s growing Corporate & Securities practice. Katy Reamon will join Scale LLP as its new Corporate & Securities Co-Practice Group Leader.

The team expands Scale’s existing Colorado and Oregon footprints, bringing a sophisticated M&A, corporate and commercial transactions practice that serves a wide variety of high-growth industries, including SaaS and software deployment, biotech and medical devices, clean tech, venture capital and private equity.

This announcement follows recent news on Scale’s boutique firm acquisitions. As the premium national distributed firm, Scale sees opportunity in national expansion through strategic partnerships.

“Katy, Channah and their team are business lawyers and entrepreneurs with experience serving clients across every stage of growth,” said Scale Managing Partner David Reidy. “We were impressed by their practice, but as we got to know the team we also realized that they see the evolution and transformation of legal practice the same way we do. I couldn’t be more excited to welcome them to Scale and to continue building a national firm together,” said Reidy. “Katy Reamon’s role as Corporate & Securities Co-Practice Group Leader at Scale signals our belief in this team and our growth strategy. She’s an amazing addition to our leadership team.”

Reamon was attracted to Scale because of the firm’s entrepreneurial roots and collective culture. “Team is important to us, and we wanted to grow our practice by becoming part of a highly collaborative community that has a national reach,” Reamon said. “We share many core values, like humility, empathy, entrepreneurship, and inclusivity, and we are aligned in our desire to make the practice of law sustainable and fulfilling. We share that with other attorneys at Scale and are looking forward to complementing practice areas to address an even wider range of our clients’ day-to-day legal needs.”

“I was initially impressed by the caliber of attorneys at Scale. Everyone has a resume that screams ‘Excellence!’ But what won me over was the palpable energy and excitement I felt from every single attorney I spoke to,” said Partner Channah Rose. “It felt like a group of people that know they are building something truly unique and are having a blast doing it.”

Associates Jenna Geuke and Tyler Hayden will also join Scale. Geuke is a corporate and commercial attorney who takes a business-minded approach to legal solutions. Having worked as in-house counsel at Techstars, a top global accelerator company with an investment portfolio of over 2,500 companies, her experience has given her a deep familiarity with high-growth start-up challenges. Tyler Hayden is also a corporate and commercial attorney with a passion for entrepreneurship. It was Colorado’s thriving entrepreneurial scene that lured Tyler to relocate, and now startups rely on him to deliver practical legal advice.

The boutique team addition is the continuation of what Scale sees as a wave of opportunity to expand through strategic partnerships, leveraging technology and the new post-pandemic shift to a less localized practice of law. Scale VP of Talent, Jessica Sisco, who leads the firm’s recruiting initiatives, sees an uptick of high-quality boutique teams with interest in partnering with the growing Scale community. “Boutique law firm teams are seeing the opportunity to build fulfilling practices as part of a larger, remote firm network of high-caliber attorneys. They can share in collective practice success without having to shoulder the burdens of running the back-office,” observes Sisco. “It’s a no brainer for many boutique teams.”

About Scale LLP

Called the “Wave of the Future” by Reuters, Scale LLP is a full-service distributed law firm built by Silicon Valley founders and GCs to provide an alternative to a traditional private practice. In addition to serving as general counsel, Scale attorneys have been founders and entrepreneurs, have served in BigLaw and in government, and have learned their trade in the courtroom. Scale brings real-world experience and the benefits of a fully-remote work structure to provide expertise and value to clients across its Corporate & Securities, General Counsel Services, Fintech & Financial Services, Real Estate & Land Use, Litigation and IP practices nationally.

Learn more at www.scalefirm.com.

Media Contact

Kris Vann, VP of Marketing, Scale LLP, 1 4157355933, [email protected], https://www.scalefirm.com/

SOURCE Scale LLP

Legal / Law: Criminal Law

Colossal Announces Over $9 Million Raised From Fab Over 40 Competition Benefiting National Breast Cancer Foundation

Leave a comment


The team at NBCF expressed their gratitude to Colossal: “You all continue to amaze us. THANK YOU for raising this transformational, life-changing gift of over $9 million! With your continued support, you are bringing joy, hope, and help to hundreds of thousands of women and their families. We can’t think of anything better. You all are angels.”

Colossal is one of the greatest benefactors of the National Breast Cancer Foundation, raising $17,221,770.10 for grants to the organization in two years.

Introducing the 2023 Fab Over 40 Winner: Gina De Simone
Gina De Simone is the personification of being totally fabulous over 40. This licensed psychologist stays thriving at 43 by practicing yoga daily, running marathons, and focusing on inspiring others to be their best selves. “Being over 40 means the best is yet to come! I am the happiest, healthiest, and most confident I have ever been and will never let my age limit me. I am in the best decade of my life,” said De Simone, who will flaunt her health and wisdom for the world to see in the pages of NewBeauty Magazine in 2024.

About NewBeauty Magazine
NewBeauty Magazine is “the definitive authority on all things beauty.” Since its inception, this extraordinary magazine has established a unique position as the sole publication entirely devoted to beauty. Its aim is to motivate, educate, and assist women in making intelligent, well-informed, and self-assured beauty decisions.

Fab Over 40 is sponsored by TestTube, NewBeauty’s editor-curated subscription box, and BeautyPass, an invite-only free membership that provides exclusive offers, gifts, and access to VIP events for its members.

About Colossal
Colossal is a nationally registered professional fundraiser that inspires people to advocate for themselves and those in need. Through online competitions like America’s Favorite Pet, Fab Over 40, and Greatest Baker, participants have the opportunity to make their mark while also making a big impact. Colossal competitions serve as fundraising campaigns for DTCare, a United States 501(c)(3) public charity organization, which then grants donation funds to specified charities at the completion of the competitions. Learn more at colossal.org.

Media Contact

Anne-Marie Pritchett, Colossal Management, (602) 633-4163, [email protected], Colossal Management

Twitter

SOURCE Colossal Management



Health

ClinicMind Acquires Genesis Chiropractic Software and Names Dr. Brian Capra a President of the Professional Services Division of ClinicMind

Leave a comment


“The Genesis acquisition completes a series of five acquisitions planned for 2023 and positions ClinicMind as the #1 EHR software in the Chiropractic Software space,” said Dr. Yuval Lirov, CEO of ClinicMind. “I am excited to have Dr. Brian Capra preside over our Professional Services Division and extend the ClinicMind leadership ranking beyond the chiropractic specialty.”

“Together, we can access more resources to improve the patient experience, practice revenue, staff efficiency, and provider compliance,” continued Capra. “Our team will expand globally to build automated workflows, big data analysis, and Artificial Intelligence (AI) tools for better visibility of patient outcomes and improved research data sharing. Most importantly, our combined human resources share the same core values of Excellence, Teamwork, and Learning, and by working together, we will bring in a new era of advanced yet easy-to-use technology, ultimately driving toward a more efficient and patient-centered healthcare industry.”

“This acquisition is another example of a seamless transition for our clients, demonstrating our commitment to maintaining uninterrupted service levels throughout integrations and new client setup processes,” concluded Lirov. “By leveraging ClinicMind integrations with other EHR systems, such as Epic, WebPT, and Netsmart, combined with a White Gloves Service, ClinicMind achieves unprecedented levels of ease of setup, allowing the clients to continue to use their familiar EHR software while delivering cost-efficient practice management and billing solutions and maintaining service excellence standards.”

About ClinicMind

ClinicMind is a leading provider of comprehensive Software as a Service (SaaS) solutions and software-enabled RCM services in the Healthcare industry. ClinicMind’s ONC-certified software solution includes a multi-specialty EHR Platform as a Service (PaaS), practice management software, mobile EHR, a patient portal, and dozens of integrated applications for Patient Relationship Management, Clinical Compliance, Patient Education, Credit Card processing, and other specialty EHRs. ClinicMind’s RCM services include full-service multi-specialty medical billing services, credentialing, medical coding, and prior authorization services. Visit http://www.clinicmind.com for more information.

About Genesis Chiropractic Software

Genesis Chiropractic Software was designed by chiropractic business owners with both patient relationship management and practice profitability in mind. Genesis provides a complete chiropractic practice management solution and RCM service that supports every role in busy chiropractic practice, from the owners and practitioners to the front desk and back office. It automates most standard tasks, including patient relationship management, revenue cycle management, compliance, and office management. Its exclusive workflow functionality continuously improves productivity, control, and predictability, fostering teamwork and time savings, which leads to greater profitability and practice growth. Visit http://www.genesischiropracticsoftware.com for more information.

Media Contact

Emily Burke, ClinicMind, 1 (234) 254-2255, [email protected], http://www.ClinicMind.com

SOURCE ClinicMind

Health

A Unique Blend of Functionality and Fun

Leave a comment


Functional Collagen Sticks come in four different varieties, each supporting different health functions. Vitality Support chews contain energy-boosting ingredients like ginger, banana, mango, and coconut oil to strengthen immunity and support digestion. Immune Support chews contain vitamins A and E, flaxseed oil, turmeric, and omega-3s to strengthen immunity and support eye health and brain function. Hip & Joint chews are packed with glucosamine and chondroitin to repair joints, improve mobility, and reduce pain. Skin & Coat chews contain flaxseed oil, vitamin E, biotin, and omega-3s and 6s for healthier skin, a shinier coat, and reduced irritation.

Crafted for medium chewers, these 5″ sticks cater to diverse tastes and needs. Like all Natural Farm products, Functional Collagen Sticks are hormone-free and chemical-free. They have received incredible reviews from pet owners who appreciate the benefits these chews provide.

Natural Farm is committed to analyzing health trends to identify ingredients that have proven to be beneficial to dogs. Their goal is to provide healthy, natural, and long-lasting entertainment while driving innovation in the pet products industry.

About Natural Farm: Specializing in all-natural dog treats, chews, and bones featuring single or limited ingredients, Natural Farm exemplifies dedication to quality, innovation, and responsible sourcing. They stand out for their commitment to excellence, which is evident in every product they create.

Media Contact

Trust Relations PR, [email protected]

SOURCE Natural Farm

Health

BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare

Leave a comment


“We are excited to partner with a company as innovative and capable as Celularity, whose exceptional leadership makes this endeavor and mission a pleasure. There is a tremendous opportunity to assist oral healthcare practitioners managing very challenging indications, which often involve long, recurring, and painful procedures requiring many visits. BioCellgraft intends to help change this paradigm by bringing Celularity’s exceptional biomaterial products to the dental market in the United States,” said Michel Dard, DDS, MS, Ph.D., BioCellgraft’s CEO. Dr. Dard is a well-known expert and author on dental practices involving implantology and has trained and educated many clinicians in oral care around the world while also holding post as a leading executive with major dental entities globally. “With Michel Dard leading our organization, our reach to practitioners in the oral healthcare market spans to every inch of the globe, giving us the opportunity to provide patients in need access to this innovative biomaterial technology,” said Michael Wilhelm, Founder, Chairman and EVP of Partnerships and Investor Relations.

According to Precedence Research, the global dental implant market was estimated at US$4.05 billion in 2022 and is expected to reach US$6.31 billion in the U.S. by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. The U.S. dental implant and final abutment market is valued at US$1.4 billion in 2022 and expected to increase over the forecast period at a CAGR of 6.4% to reach US$2.2 billion in 2029 according to ResearchAndMarkets.com. In addition, the gingivitis/periodontal market involving the necessary treatment of soft and hard tissue (gum and bone) has a market value of US$7 billion according to Future Market Insights. “Studies have determined that in the age group of 20-35 years, 43.25% of individuals have a thin gingival biotype. This staggering number of individuals implies a very large number of likely procedures in addition to procedures to treat other diseases that we anticipate supporting with these biomaterials,” said Dr. Dard.

“Oral health is fundamental to general health and wellness and has far reaching impacts on quality of life. The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions. I believe this represents a very large, currently under-served market opportunity and am very excited to work with renowned experts such as Dr. Dard and his team to deploy existing technology as well as innovate together to address a wide range of dental and oral surgical conditions” said Robert J. Hariri, M.D., Ph.D., Celularity’s Founder, CEO, and Chairman.

Terms of the agreement are not disclosed.

About BioCellgraft, Inc.

In the realm of oral health, the absence of effective regenerative therapies for soft and hard tissues remains a significant concern. Patients worldwide grapple with issues such as degenerating gums, gum recession, and thin biotypes, necessitating innovative solutions.

BioCellgraft is a pioneering oral healthcare focused development and commercialization company driven by experienced dental experts and educators aimed at revolutionizing oral healthcare through groundbreaking regenerative therapies. BioCellgraft represents the epitome of innovation in oral healthcare, catering to unmet needs within the dental landscape. Our focus lies in the development and delivery of regenerative treatments that enhance both soft and hard tissues in the oral cavity. Leveraging the Human Connective Tissue Matrix (HCTM), our suite of products introduces novel possibilities in tissue regeneration.

To learn more, visit: www.biocellgraft.com Visit www.celularity.com

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing, and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based

BioCellgraft, Inc. Investor Contact:
Michael Wilhelm, Founder, Chairman and EVP of Partnerships and Investor Relations
[email protected]
1-646-502-5501 EXT 102

Media Contact
Michael Wilhelm, BioCellgraft, 1 646-502-5501 102, [email protected], https://biocellgraft.com

SOURCE BioCellgraft

Health

InVivo Biosystems Secures New Investment to Accelerate CRISPR Innovation

Leave a comment


“The new investment in our corporate vision at a time when CRISPR’s capabilities to transform therapeutic outcomes is worldwide news, will fuel existing innovation initiatives and breakthrough capabilities,” said Matt Beaudet, Chief Executive Officer, InVivo Biosystems. “The financial infusion coupled with the appointment of new Board Chairman C. Palani Palaniappan puts the Company in an exciting position to make even further breakthroughs in 2024.”

C. Palani Palaniappan shared his perspective on the Invivo Biosystems opportunity, “The transformative power of CRISPR in real-world applications is becoming evident through recent drug approvals in curing sickle cell anemia or many forms of blood cancer are paradigm changing concepts of ‘living drugs.’ InVivo’s core IP and expertise in CRISPR gene engineering in model organisms are helping accelerate drug discovery with both rapid turnaround and affordability. It offers a compelling case for many biotech and pharma partners to capitalize on. I am thrilled to support the InVivo Biosystems team alongside the other accomplished board members to realize the full potential of CRISPR capabilities in revolutionizing medical innovation for the 21st Century.”

Most recently InVivo Biosystems has seen its solutions validated via new technology patents and key grants for further product development.

  • Funding for AI-based Monitoring of Zebrafish: InVivo Biosystems was awarded a $2.8M Fast-Track SBIR grant from the NIH to create an automated, AI-based monitoring system for zebrafish in its home tanks, easing the burden on facility managers and enabling enhanced reproducibility of scientific results. This is particularly important for combining this technology with genome-edited fish that recapitulate human diseases, allowing for automated deep phenotyping that can aid in drug discovery efforts.
  • Licensing of a High Throughput CRISPR Technology: the University of Utah issued an exclusive license to InVivo Biosystems for a new CRISPR-enabling technology named MIC-Drop. The technology partitions CRISPR reagents into microfluidic droplets, enabling multiplexed creation and delivery of genetic knockouts in vivo. The technology mimics a traditional forward genetic screen for the identification of targets, combining that with intelligent design and intentional selection of genes and subdomains.
  • Granting of an Innovative Patent for Animal Humanization: InVivo Biosystems was granted a patent on its technology to create transgenic research animals bearing human versions of disease-causing genes. This innovative patent increases the translational potential for discovering new target-based drugs in animal models with completely orthologous targets or binding domains.

InVivo Biosystems

Eugene, Ore.-based InVivo Biosystems, experts in CRISPR genome editing, provides end-to-end preclinical services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate research and drug development efforts. The company’s mission is to build the world’s most effective genetic animal models to advance human health. With its CRISPR genome editing platform, InVivo Biosystems creates custom genome-edited C. elegans and zebrafish models for preclinical studies and drug discovery. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies to help accelerate decision-making in the early-stage development of new compounds. For more information, visit http://www.invivobiosystems.com.

Media Contact

Shula Jaron, InVivo Biosystems, 1 541-844-5057, [email protected], https://invivobiosystems.com/

Laura Taylor, Taylor Strategic Communications, 1 720-556-2640, [email protected]

SOURCE InVivo Biosystems

health and fitness

BioCellgraft Finalizes Commercialization Agreement with Celularity For The Manufacture and Distribution of Products for Therapeutic Use in Oral Healthcare

Leave a comment


“We are excited to partner with a company as innovative and capable as Celularity, whose exceptional leadership makes this endeavor and mission a pleasure. There is a tremendous opportunity to assist oral healthcare practitioners managing very challenging indications, which often involve long, recurring, and painful procedures requiring many visits. BioCellgraft intends to help change this paradigm by bringing Celularity’s exceptional biomaterial products to the dental market in the United States,” said Michel Dard, DDS, MS, Ph.D., BioCellgraft’s CEO. Dr. Dard is a well-known expert and author on dental practices involving implantology and has trained and educated many clinicians in oral care around the world while also holding post as a leading executive with major dental entities globally. “With Michel Dard leading our organization, our reach to practitioners in the oral healthcare market spans to every inch of the globe, giving us the opportunity to provide patients in need access to this innovative biomaterial technology,” said Michael Wilhelm, Founder, Chairman and EVP of Partnerships and Investor Relations.

According to Precedence Research, the global dental implant market was estimated at US$4.05 billion in 2022 and is expected to reach US$6.31 billion in the U.S. by 2030 and poised to grow at a compound annual growth rate (CAGR) of 5.7% from 2022 to 2030. The U.S. dental implant and final abutment market is valued at US$1.4 billion in 2022 and expected to increase over the forecast period at a CAGR of 6.4% to reach US$2.2 billion in 2029 according to ResearchAndMarkets.com. In addition, the gingivitis/periodontal market involving the necessary treatment of soft and hard tissue (gum and bone) has a market value of US$7 billion according to Future Market Insights. “Studies have determined that in the age group of 20-35 years, 43.25% of individuals have a thin gingival biotype. This staggering number of individuals implies a very large number of likely procedures in addition to procedures to treat other diseases that we anticipate supporting with these biomaterials,” said Dr. Dard.

“Oral health is fundamental to general health and wellness and has far reaching impacts on quality of life. The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.  I believe this represents a very large, currently under-served market opportunity and am very excited to work with renowned experts such as Dr. Dard and his team to deploy existing technology as well as innovate together to address a wide range of dental and oral surgical conditions” said Robert J. Hariri, M.D., Ph.D., Celularity’s Founder, CEO, and Chairman.  

Terms of the agreement are not disclosed.

About BioCellgraft, Inc.

In the realm of oral health, the absence of effective regenerative therapies for soft and hard tissues remains a significant concern. Patients worldwide grapple with issues such as degenerating gums, gum recession, and thin biotypes, necessitating innovative solutions.
BioCellgraft is a pioneering oral healthcare focused development and commercialization company driven by experienced dental experts and educators aimed at revolutionizing oral healthcare through groundbreaking regenerative therapies. BioCellgraft represents the epitome of innovation in oral healthcare, catering to unmet needs within the dental landscape. Our focus lies in the development and delivery of regenerative treatments that enhance both soft and hard tissues in the oral cavity. Leveraging the Human Connective Tissue Matrix (HCTM), our suite of products introduces novel possibilities in tissue regeneration.

To learn more, visit: www.biocellgraft.com

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are based on expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing, and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Celularity expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

BioCellgraft, Inc. Investor Contact:
Michael Wilhelm, Founder, Chairman and EVP of Partnerships and Investor Relations
[email protected]
1-646-502-5501 EXT 102

SOURCE BioCellgraft